<article article-type="case-report" dtd-version="1.4" xml:lang="en"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Eur Heart J Case Rep</journal-id><journal-id journal-id-type="iso-abbrev">Eur Heart J Case Rep</journal-id><journal-id journal-id-type="pmc-domain-id">3538</journal-id><journal-id journal-id-type="pmc-domain">ehjcr</journal-id><journal-id journal-id-type="publisher-id">ehjcr</journal-id><journal-title-group><journal-title>European Heart Journal. Case Reports</journal-title></journal-title-group><issn pub-type="epub">2514-2119</issn><publisher><publisher-name>Oxford University Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12914574</article-id><article-id pub-id-type="pmcid-ver">PMC12914574.1</article-id><article-id pub-id-type="pmcaid">12914574</article-id><article-id pub-id-type="pmcaiid">12914574</article-id><article-id pub-id-type="pmid">41717124</article-id><article-id pub-id-type="doi">10.1093/ehjcr/ytag081</article-id><article-id pub-id-type="publisher-id">ytag081</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Case Report</subject><subj-group subj-group-type="category-toc-heading"><subject>Medical Management of Arrhythmias</subject></subj-group></subj-group><subj-group subj-group-type="category-taxonomy-collection"><subject>AcademicSubjects/MED00200</subject></subj-group><subj-group subj-group-type="category-taxonomy-collection"><subject>Eurheartj/14</subject></subj-group></article-categories><title-group><article-title>Dabigatran-induced acute hepatitis in a patient with atrial fibrillation: a rare case report</article-title></title-group><contrib-group><contrib contrib-type="author"><contrib-id authenticated="false" contrib-id-type="orcid">https://orcid.org/0009-0002-2915-9827</contrib-id><name name-style="western"><surname>Hsu</surname><given-names initials="CW">Chih-Wei</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization">Visualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Writing - original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft">Writing - original draft</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Writing - review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing">Writing - review &amp; editing</role><aff>
<institution>Department of Pharmacy, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation</institution>, <addr-line>No. 707, Sec. 3, Zhongyang Road, Hualien City, Hualien County 970473</addr-line>,<country country="TW">Taiwan</country></aff></contrib><contrib contrib-type="author"><name name-style="western"><surname>Chang</surname><given-names initials="HR">Huai-Ren</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Data curation" vocab-term-identifier="https://credit.niso.org/contributor-roles/data-curation">Data curation</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision">Supervision</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Writing - review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing">Writing - review &amp; editing</role><aff>
<institution>School of Medicine, Tzu Chi University</institution>, <addr-line>No. 701, Sec. 3, Zhongyang Road, Hualien City, Hualien County 970374</addr-line>, <country country="TW">Taiwan</country></aff><aff>
<institution>Division of Cardiology, Department of Internal Medicine, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation</institution>, <addr-line>No. 707, Sec. 3, Zhongyang Road, Hualien City, Hualien County 970473</addr-line>, <country country="TW">Taiwan</country></aff></contrib><contrib contrib-type="author" corresp="yes"><contrib-id authenticated="false" contrib-id-type="orcid">https://orcid.org/0009-0007-4679-5856</contrib-id><name name-style="western"><surname>Wu</surname><given-names initials="SC">Shan-Chieh</given-names></name><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Visualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/visualization">Visualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org" vocab-term="Writing - review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing">Writing - review &amp; editing</role><aff>
<institution>Department of Pharmacy, Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation</institution>, <addr-line>No. 707, Sec. 3, Zhongyang Road, Hualien City, Hualien County 970473</addr-line>,<country country="TW">Taiwan</country></aff><aff>
<institution>Graduate Institute of Clinical Pharmacy, College of Medicine, National Taiwan University</institution>, <addr-line>No. 33, Linsen S. Road, Zhongzheng District, Taipei City 100025</addr-line>, <country country="TW">Taiwan</country></aff><xref ref-type="corresp" rid="ytag081-cor1"/><xref ref-type="author-notes" rid="FN01"/></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name name-style="western"><surname>Heeger</surname><given-names initials="CHH">Christian-Hendrik Hendrik</given-names></name><role>Handling Editor</role></contrib><contrib contrib-type="editor"><name name-style="western"><surname>Fink</surname><given-names initials="T">Thomas</given-names></name><role>Editor</role></contrib><contrib contrib-type="editor"><name name-style="western"><surname>Feickert</surname><given-names initials="S">Sebastian</given-names></name><role>Editor</role></contrib><contrib contrib-type="editor"><name name-style="western"><surname>Ranganathan</surname><given-names initials="D">Deepti</given-names></name><role>Editor</role></contrib></contrib-group><author-notes><corresp id="ytag081-cor1">Corresponding author. Tel: +886-38-561825, Email: <email>d10451003@ntu.edu.tw</email></corresp><fn fn-type="COI-statement" id="FN01"><p>
<italic toggle="yes">Conflict of interest</italic>. None declared.</p></fn></author-notes><pub-date pub-type="collection"><month>2</month><year>2026</year></pub-date><pub-date iso-8601-date="2026-01-31" pub-type="epub"><day>31</day><month>1</month><year>2026</year></pub-date><volume>10</volume><issue>2</issue><issue-id pub-id-type="pmc-issue-id">506644</issue-id><elocation-id>ytag081</elocation-id><history><date date-type="received"><day>22</day><month>9</month><year>2025</year></date><date date-type="rev-recd"><day>10</day><month>12</month><year>2025</year></date><date date-type="accepted"><day>28</day><month>1</month><year>2026</year></date><date date-type="corrected-typeset"><day>18</day><month>2</month><year>2026</year></date></history><pub-history><event event-type="pmc-release"><date><day>31</day><month>01</month><year>2026</year></date></event><event event-type="pmc-live"><date><day>19</day><month>02</month><year>2026</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2026-02-20 09:25:12.637"><day>20</day><month>02</month><year>2026</year></date></event></pub-history><permissions><copyright-statement>© The Author(s) 2026. Published by Oxford University Press on behalf of the European Society of Cardiology.</copyright-statement><copyright-year>2026</copyright-year><license><ali:license_ref content-type="ccbynclicense" specific-use="textmining" xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by-nc/4.0/</ali:license_ref><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nc/4.0/" xmlns:xlink="http://www.w3.org/1999/xlink">https://creativecommons.org/licenses/by-nc/4.0/</ext-link>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.</license-p></license></permissions><self-uri content-type="pmc-pdf" xlink:href="ytag081.pdf" xmlns:xlink="http://www.w3.org/1999/xlink"/><self-uri xlink:href="ytag081.pdf" xmlns:xlink="http://www.w3.org/1999/xlink"/><abstract><title>Abstract</title><sec id="s1"><title>Background</title><p>Dabigatran etexilate is a prodrug converted into active dabigatran, a reversible thrombin inhibitor, after oral administration. The Food and Drug Administration approved it for stroke prevention in non-valvular atrial fibrillation patients and for treating deep venous thrombosis and pulmonary embolism. In the Randomized Evaluation of Long-Term Anticoagulation Therapy trial, dabigatran demonstrated non-inferior efficacy and reduced haemorrhagic stroke risk compared with warfarin. Herein, we present a rare case of a patient with atrial fibrillation who developed acute hepatitis following dabigatran initiation.</p></sec><sec id="s2"><title>Case summary</title><p>A 69-year-old man with a history of hypertension, diabetes, and recent non-ST elevation acute coronary syndrome underwent drug-eluting stent placement in October 2024. He was discharged on antiplatelets, heart failure, and diabetes therapies. On 12 November 2024, dabigatran 110 mg twice daily was added for atrial fibrillation stroke prevention, discontinuing aspirin. Two weeks later, the patient presented with decreased appetite, epigastric discomfort, dark urine, weight loss, and constipation. Laboratory tests revealed elevated hepatic enzymes, excluding viral and other aetiologies. After discontinuing dabigatran, the liver enzymes normalized during hospitalization. He was discharged on 11 December 2024, and his anticoagulant was switched to edoxaban during the follow-up visit a week later. Liver function remained normal since then.</p></sec><sec id="s3"><title>Discussion</title><p>This case highlights drug-induced liver injury (DILI) rarely attributed to dabigatran, despite proper dosing. Notably, ticagrelor, a <italic toggle="yes">P</italic>-glycoprotein (P-gp) inhibitor, was concurrently administered, which might have increased dabigatran exposure, contributing to hepatotoxicity. Clinicians should remain vigilant for DILI in patients on dabigatran—particularly those on P-gp inhibitors—and monitor hepatic function.</p></sec></abstract><kwd-group><kwd>Anticoagulants</kwd><kwd>Atrial fibrillation</kwd><kwd>Chemical and drug-induced liver injury</kwd><kwd>Dabigatran</kwd><kwd>Case report</kwd></kwd-group><funding-group><award-group award-type="grant"><funding-source>
<institution-wrap><institution>Hualien Tzu Chi Hospital</institution><institution-id institution-id-type="DOI">10.13039/501100022298</institution-id></institution-wrap>
</funding-source></award-group><award-group award-type="grant"><funding-source>
<institution-wrap><institution>Buddhist Tzu Chi Medical Foundation</institution><institution-id institution-id-type="DOI">10.13039/501100005925</institution-id></institution-wrap>
</funding-source></award-group></funding-group><counts><page-count count="5"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-license-ref</meta-name><meta-value>CC BY-NC</meta-value></custom-meta></custom-meta-group></article-meta></front><body><boxed-text id="ytag081-box1" orientation="portrait" position="anchor"><label>Learning points</label><list list-type="bullet"><list-item><p>Clinicians should consider dabigatran as a possible cause of hepatic dysfunction if liver enzyme elevations occur after initiation.</p></list-item><list-item><p>Monitor liver function closely when use dabigatran concomitantly with P-glycoprotein (P-gp) inhibitors like ticagrelor.</p></list-item></list></boxed-text><sec id="ytag081-s1" sec-type="intro"><title>Introduction</title><p>Dabigatran etexilate is a prodrug that is converted <italic toggle="yes">in vivo</italic> by carboxylesterases into an active form, dabigatran.<sup><xref ref-type="bibr" rid="ytag081-B1">1</xref></sup> This active compound reversibly binds to the active site of the thrombin molecule, inhibiting thrombin-mediated activation of coagulation factors.<sup><xref ref-type="bibr" rid="ytag081-B1">1</xref></sup> Dabigatran etexilate was approved by the U.S. Food and Drug Administration in October 2010 for stroke prevention in patients with non-valvular atrial fibrillation (AF).<sup><xref ref-type="bibr" rid="ytag081-B2">2</xref></sup> In April 2014, it received an additional approval for the treatment of deep venous thrombosis and pulmonary embolism.<sup><xref ref-type="bibr" rid="ytag081-B3">3</xref></sup></p><p>The Randomized Evaluation of Long-Term Anticoagulation Therapy trial demonstrated that dabigatran is non-inferior to warfarin regarding efficacy and is associated with a lower incidence of haemorrhagic stroke.<sup><xref ref-type="bibr" rid="ytag081-B4">4</xref></sup> Furthermore, dabigatran is more convenient, as it does not require regular international normalized ratio monitoring.<sup><xref ref-type="bibr" rid="ytag081-B4">4</xref></sup> Thus, since 2010, anticoagulation strategies for stroke prevention in AF patients have gradually shifted from warfarin to direct oral anticoagulants (DOACs), including dabigatran.<sup><xref ref-type="bibr" rid="ytag081-B5">5</xref></sup></p><p>The most commonly reported adverse reactions associated with dabigatran include bleeding and gastrointestinal disorders, whereas hepatic adverse events are extremely rare.<sup><xref ref-type="bibr" rid="ytag081-B6">6</xref></sup> Herein, we present the case of a patient with AF who developed acute hepatitis following dabigatran initiation for stroke prevention.</p></sec><sec id="ytag081-s2"><title>Summary figure</title><fig fig-type="figure" id="ytag081-F3" orientation="portrait" position="float"><caption><p>AF, atrial fibrillation; ALT, alanine aminotransferase; AST, aspartate aminotransferase; NSTE-ACS, non-ST-segment elevation acute coronary syndrome.</p></caption><graphic orientation="portrait" position="float" xlink:href="ytag081il2.jpg" xmlns:xlink="http://www.w3.org/1999/xlink"/></fig></sec><sec id="ytag081-s3"><title>Case presentation</title><p>A 69-year-old male was admitted for acute hepatitis on 29 November 2024. Prior to this admission, he had been hospitalized from October 11th to 22nd, 2024 for non-ST-segment elevation acute coronary syndrome (ACS) (NSTE-ACS). The patient had a medical history of hypertension, diabetes mellitus, and poor adherence to prescribed medications. A drug-eluting stent (3.5 × 48 mm and 3.0 × 48 mm) was implanted in the proximal-to-mid left anterior descending artery on 18 October 2024. He was also diagnosed with heart failure with reduced ejection fraction, with a left ventricular ejection fraction of 31%, as well as AF. Upon discharge, the patient was prescribed medications including: aspirin 100 mg daily; ticagrelor 90 mg twice a day; nicorandil 5 mg twice a day; valsartan 20 mg twice a day; metformin 500 mg twice a day; empagliflozin/linagliptin 25/5 mg daily; bisoprolol 2.5 mg daily; and spironolactone 12.5 mg daily.</p><p>On 12 November 2024, dabigatran etexilate 110 mg twice daily was initiated for stroke prevention in the setting of AF, given that his creatinine clearance was 65.85 mL/min during a follow-up visit. At that time, all other previously prescribed medications were continued except for aspirin.</p><p>During the second follow-up on 26 November 2024, the patient reported poor appetite, epigastric pain, a weight loss of 6 kg, dark-yellow urine, and constipation. Laboratory test results revealed significantly elevated liver enzymes (<italic toggle="yes"><xref ref-type="fig" rid="ytag081-F1">Figure 1</xref></italic>). A detailed history was obtained to exclude any recent dietary changes, alcohol consumption, use of herbal or dietary supplements, or illicit drug use. Given that dabigatran-induced liver injury was suspected, the medication was discontinued; the patient was admitted for further evaluation.</p><fig fig-type="figure" id="ytag081-F1" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Trend of the patient’s liver function tests. ALT, alanine aminotransferase; AST, aspartate aminotransferase.</p></caption><graphic orientation="portrait" position="float" xlink:href="ytag081f1.jpg" xmlns:xlink="http://www.w3.org/1999/xlink"/></fig><p>Upon admission, all outpatient medications were continued, except for dabigatran, which was suspected to be the causative agent of the patient’s liver injury. An abdominal ultrasonography performed on 2 December 2024 showed mild fatty liver and gallbladder sludge. Testing for viral hepatitis was negative, including anti-HAV IgM (S/CO 0.28), HBsAg (S/CO 0.39) with non-reactive anti-HBs, and anti-HCV (S/CO 0.13). Liver function enzymes and bilirubin levels were monitored regularly and returned to normal after dabigatran discontinuation (<italic toggle="yes"><xref ref-type="fig" rid="ytag081-F1">Figures 1</xref></italic> and <italic toggle="yes"><xref ref-type="fig" rid="ytag081-F2">2</xref></italic>). The patient’s condition remained clinically stable and was discharged on 11 December 2024. Due to the ongoing risk of thromboembolism associated with AF, the patient was switched to edoxaban during the follow-up visit on 17 December 2024. Subsequent liver function tests on 30 December 2024 showed results within normal ranges.</p><fig fig-type="figure" id="ytag081-F2" orientation="portrait" position="float"><label>Figure 2</label><caption><p>Trend of the patient’s total and direct bilirubin levels.</p></caption><graphic orientation="portrait" position="float" xlink:href="ytag081f2.jpg" xmlns:xlink="http://www.w3.org/1999/xlink"/></fig></sec><sec id="ytag081-s4" sec-type="discussion"><title>Discussion</title><p>This case is a rare instance of drug-induced liver injury (DILI) caused by dabigatran. DILI associated with DOACs is uncommon overall.<sup><xref ref-type="bibr" rid="ytag081-B7">7</xref>,<xref ref-type="bibr" rid="ytag081-B8">8</xref></sup> A systematic review identified 27 cases of DOAC-related DILI across 15 studies, with only three cases attributed to dabigatran.<sup><xref ref-type="bibr" rid="ytag081-B7">7</xref></sup> A meta-analysis of 29 randomized controlled trials involving 152,116 patients found no significant increase in the risk of DILI associated with DOACs.<sup><xref ref-type="bibr" rid="ytag081-B8">8</xref></sup> Moreover, among DOACs, dabigatran appears less likely to cause elevation of liver enzymes compared with the control group.<sup><xref ref-type="bibr" rid="ytag081-B8">8</xref></sup></p><p>Our patient, diagnosed with NSTE-ACS, heart failure, and AF, had a CHA<sub>2</sub>DS<sub>2</sub>-VASc score of 5, indicating a high thrombotic risk with an estimated unadjusted ischaemic stroke rate of 7.2% per year.<sup><xref ref-type="bibr" rid="ytag081-B9">9</xref></sup> The recommendations from the 2023 ESC ACS guidelines, patients with ACS and AF should receive oral anticoagulation when the CHA₂DS₂-VASc score is ≥1 point in men and ≥2 points in women, in addition to a P2Y<sub>12</sub> receptor inhibitor.<sup><xref ref-type="bibr" rid="ytag081-B10">10</xref></sup> In alignment with the guideline, our patient was started on dabigatran alongside ticagrelor for stroke prevention and NSTE-ACS treatment, although it was not added during the October admission, but later at the first follow-up visit.</p><p>The patient had no history of liver disease but developed acute hepatitis (ALT 1064 U/L, AST 589 U/L, ALP 109 IU/L on 26 November 2024) after receiving dabigatran at a dose appropriate for his renal function. He remained hemodynamically stable, without signs of shock, and with normal jugular venous pressure during the second follow-up visit on 26 November 2024, and throughout his subsequent hospital admission. After discontinuing the suspected agent, dabigatran, the patient demonstrated a ≥ 50% improvement in liver function within one week (ALT 392 U/L, AST 71 U/L on 2 December 2024). The Rousself Uclaf Causality Assessment Method (RUCAM) score was calculated, yielding a score of 8 (<italic toggle="yes"><xref ref-type="table" rid="ytag081-T1">Table 1</xref></italic>).<sup><xref ref-type="bibr" rid="ytag081-B11">11</xref></sup> Accordingly, the case was diagnosed with DILI due to dabigatran.</p><table-wrap id="ytag081-T1" orientation="portrait" position="float"><label>Table 1</label><caption><p>RUCAM causality assessment</p></caption><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" span="1"/><col align="left" span="1"/><col align="center" span="1"/></colgroup><thead><tr><th align="left" colspan="1" rowspan="1">Item</th><th align="center" colspan="1" rowspan="1">Descriptions</th><th align="center" colspan="1" rowspan="1">Case scores</th></tr></thead><tbody><tr><td colspan="1" rowspan="1">Types of injury</td><td colspan="2" rowspan="1">R ratio &gt;5, hepatocellular type</td></tr><tr><td colspan="1" rowspan="1">Time to onset</td><td colspan="1" rowspan="1">Initial treatment, 5–90 days after initiation</td><td colspan="1" rowspan="1">+2</td></tr><tr><td colspan="1" rowspan="1">After stopping the drug</td><td colspan="1" rowspan="1">ALT decreased ≥50% within 8 days after drug discontinuation</td><td colspan="1" rowspan="1">+3</td></tr><tr><td colspan="1" rowspan="1">Risk factors</td><td colspan="1" rowspan="1">&gt;55 years old</td><td colspan="1" rowspan="1">+1</td></tr><tr><td colspan="1" rowspan="1">Concomitant drugs</td><td colspan="1" rowspan="1">No concomitant drugs with hepatotoxicity</td><td colspan="1" rowspan="1">0</td></tr><tr><td colspan="1" rowspan="1">Exclusion of other causes</td><td colspan="1" rowspan="1">Excluded acute viral hepatitis, biliary obstructive by ultrasound, recent history of hypotension, shock or ischaemia within 2 weeks of onset. No alcoholism.</td><td colspan="1" rowspan="1">+1</td></tr><tr><td colspan="1" rowspan="1">Previous information on drug’s hepatotoxicity</td><td colspan="1" rowspan="1">Not on drug’s label but previously published</td><td colspan="1" rowspan="1">+1</td></tr><tr><td colspan="1" rowspan="1">Response to readministration of drug</td><td colspan="1" rowspan="1">Not done</td><td colspan="1" rowspan="1">0</td></tr><tr><td colspan="2" rowspan="1">Total score (out of 14 points)</td><td colspan="1" rowspan="1">8</td></tr></tbody></table><table-wrap-foot><fn id="ytag081-tblfn1"><p>ALT, alanine aminotransferase.</p></fn></table-wrap-foot></table-wrap><p>Of note, this patient was prescribed ticagrelor, a known P-glycoprotein (P-gp) inhibitor, instead of clopidogrel in combination with dabigatran. Studies showed ticagrelor could increase dabigatran exposure by 26%–29%.<sup><xref ref-type="bibr" rid="ytag081-B12">12</xref></sup> Additionally, the combination use of ticagrelor and dabigatran should be avoided in patients with severe renal impairment (creatinine clearance of 15–30 mL/min).<sup><xref ref-type="bibr" rid="ytag081-B6">6</xref></sup> Unfortunately, the serum concentrations of dabigatran could not be measured at our institution, which limited our ability to determine the precise impact of ticagrelor-mediated P-gp inhibition on dabigatran exposure. As a result, we cannot ascertain the specific impact of ticagrelor-mediated P-gp inhibition on dabigatran levels and its potential contribution to DILI in our case.</p></sec><sec id="ytag081-s5"><title>Conclusion</title><p>Although our case report is limited by the absence of dabigatran serum concentration data and an autoimmune hepatitis workup, the calculated RUCAM score indicates the ‘probable’ causality between the use of dabigatran and this patient’s acute liver injury. This is supported by the exclusion of viral hepatitis, biliary obstruction, and alcohol-related liver disease, as well as the clear temporal relationship between dabigatran initiation, the onset of liver injury, and the patient’s subsequent improvement after the discontinuation of dabigatran. We report this case to raise awareness of the rare occurrence of dabigatran-associated DILI, and the interaction between ticagrelor and dabigatran might have exacerbated the condition. Although dabigatran-induced DILI is uncommon, clinicians should remain vigilant and monitor liver function after treatment initiation, particularly when dabigatran is co-administered with P-gp inhibitors, which may increase systemic exposure.</p></sec><sec id="ytag081-s6"><title>Lead author biography</title><p>
<inline-graphic xlink:href="ytag081il1.jpg" xmlns:xlink="http://www.w3.org/1999/xlink"/>
</p><p>Chih-Wei Hsu, PharmD, is currently a cardiology pharmacist at Hualien Tzu-Chi Hospital.</p></sec></body><back><ack id="ack1"><title>Acknowledgements</title><p>None declared.</p><p>
<bold>Consent:</bold> The authors confirm that written consent for submission and publication of this case report, including data and associated text, has been obtained from the patient in line with the Committee on publication ethics (COPE) guidance.</p></ack><sec id="ytag081-s7"><title>Author contributions</title><p>Chih-Wei Hsu (Conceptualization, Data curation, Visualization, Writing—original draft, Writing—review &amp; editing), Huai-Ren Chang (Conceptualization, Data curation, Supervision, Writing—review &amp; editing), and Shan-Chieh Wu (Conceptualization, Visualization, Writing—review &amp; editing)</p></sec><sec id="ytag081-s9"><title>Funding</title><p>This work was supported by Hualien Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation, Hualien, Taiwan.</p></sec><sec id="ytag081-s10" sec-type="data-availability"><title>Data availability</title><p>The data underlying this article will be shared on reasonable request to the corresponding author.</p></sec><ref-list id="ref1"><title>References</title><ref id="ytag081-B1"><label>1</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name name-style="western">
<surname>Comin</surname>  <given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Kallmes</surname>  <given-names>DF</given-names></string-name></person-group>. <article-title>Dabigatran (pradaxa)</article-title>. <source>AJNR Am J Neuroradiol</source>  <year>2012</year>;<volume>33</volume>:<fpage>426</fpage>–<lpage>428</lpage>.<pub-id pub-id-type="pmid">22345499</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.3174/ajnr.A3000</pub-id><pub-id pub-id-type="pmcid">PMC7966436</pub-id></mixed-citation></ref><ref id="ytag081-B2"><label>2</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name name-style="western">
<surname>Hankey</surname>  <given-names>GJ</given-names></string-name>, <string-name name-style="western"><surname>Eikelboom</surname>  <given-names>JW</given-names></string-name></person-group>. <article-title>Dabigatran etexilate: a new oral thrombin inhibitor</article-title>. <source>Circulation</source>  <year>2011</year>;<volume>123</volume>:<fpage>1436</fpage>–<lpage>1450</lpage>.<pub-id pub-id-type="pmid">21464059</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.1161/CIRCULATIONAHA.110.004424</pub-id></mixed-citation></ref><ref id="ytag081-B3"><label>3</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name name-style="western">
<surname>Cinteza</surname>  <given-names>M</given-names></string-name>
</person-group>. <article-title>More indications approved and safety news for dabigatran etexilate</article-title>. <source>Maedica (Bucur)</source>  <year>2014</year>;<volume>9</volume>:<fpage>405</fpage>–<lpage>407</lpage>.<pub-id pub-id-type="pmid">25705315</pub-id>
<pub-id pub-id-type="pmcid">PMC4316890</pub-id></mixed-citation></ref><ref id="ytag081-B4"><label>4</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name name-style="western">
<surname>Connolly</surname>  <given-names>SJ</given-names></string-name>, <string-name name-style="western"><surname>Ezekowitz</surname>  <given-names>MD</given-names></string-name>, <string-name name-style="western"><surname>Yusuf</surname>  <given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Eikelboom</surname>  <given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Oldgren</surname>  <given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Parekh</surname>  <given-names>A</given-names></string-name>, <etal>et al</etal></person-group>  <article-title>Dabigatran versus warfarin in patients with atrial fibrillation</article-title>. <source>N Engl J Med</source>  <year>2009</year>;<volume>361</volume>:<fpage>1139</fpage>–<lpage>1151</lpage>.<pub-id pub-id-type="pmid">19717844</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.1056/NEJMoa0905561</pub-id></mixed-citation></ref><ref id="ytag081-B5"><label>5</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name name-style="western">
<surname>Ageno</surname>  <given-names>W</given-names></string-name>, <string-name name-style="western"><surname>Caramelli</surname>  <given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Donadini</surname>  <given-names>MP</given-names></string-name>, <string-name name-style="western"><surname>Girardi</surname>  <given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Riva</surname>  <given-names>N</given-names></string-name></person-group>. <article-title>Changes in the landscape of anticoagulation: a focus on direct oral anticoagulants</article-title>. <source>Lancet Haematol</source>  <year>2024</year>;<volume>11</volume>:<fpage>e938</fpage>–<lpage>e950</lpage>.<pub-id pub-id-type="pmid">39433055</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.1016/S2352-3026(24)00281-3</pub-id></mixed-citation></ref><ref id="ytag081-B6"><label>6</label><mixed-citation publication-type="other">Boehringer Ingelheim Pharmaceuticals, Inc. <italic toggle="yes">Pradaxa® (dabigatran etexilate) capsules: prescribing information</italic> [Internet]. U.S. Food &amp; Drug Administration; revised June 2025. <ext-link ext-link-type="uri" xlink:href="https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/022512Orig1s049;214358Orig1s009correctedlbl.pdf" xmlns:xlink="http://www.w3.org/1999/xlink">https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/022512Orig1s049;214358Orig1s009correctedlbl.pdf</ext-link> (16 July 2025)</mixed-citation></ref><ref id="ytag081-B7"><label>7</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name name-style="western">
<surname>Juneja</surname>  <given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Nasa</surname>  <given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Jain</surname>  <given-names>R</given-names></string-name></person-group>. <article-title>Liver injury from direct oral anticoagulants</article-title>. <source>World J Hepatol</source>  <year>2023</year>;<volume>15</volume>:<fpage>841</fpage>–<lpage>849</lpage>.<pub-id pub-id-type="pmid">37397936</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.4254/wjh.v15.i6.841</pub-id><pub-id pub-id-type="pmcid">PMC10308284</pub-id></mixed-citation></ref><ref id="ytag081-B8"><label>8</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name name-style="western">
<surname>Caldeira</surname>  <given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Barra</surname>  <given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Santos</surname>  <given-names>AT</given-names></string-name>, <string-name name-style="western"><surname>de Abreu</surname>  <given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Pinto</surname>  <given-names>FJ</given-names></string-name>, <string-name name-style="western"><surname>Ferreira</surname>  <given-names>JJ</given-names></string-name>, <etal>et al</etal></person-group>  <article-title>Risk of drug-induced liver injury with the new oral anticoagulants: systematic review and meta-analysis</article-title>. <source>Heart</source>  <year>2014</year>;<volume>100</volume>:<fpage>550</fpage>–<lpage>556</lpage>.<pub-id pub-id-type="pmid">24476812</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.1136/heartjnl-2013-305288</pub-id></mixed-citation></ref><ref id="ytag081-B9"><label>9</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name name-style="western">
<surname>Friberg</surname>  <given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Rosenqvist</surname>  <given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Lip</surname>  <given-names>GY</given-names></string-name></person-group>. <article-title>Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish atrial fibrillation cohort study</article-title>. <source>Eur Heart J</source>  <year>2012</year>;<volume>33</volume>:<fpage>1500</fpage>–<lpage>1510</lpage>.<pub-id pub-id-type="pmid">22246443</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.1093/eurheartj/ehr488</pub-id></mixed-citation></ref><ref id="ytag081-B10"><label>10</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name name-style="western">
<surname>Byrne</surname>  <given-names>RA</given-names></string-name>, <string-name name-style="western"><surname>Rossello</surname>  <given-names>X</given-names></string-name>, <string-name name-style="western"><surname>Coughlan</surname>  <given-names>JJ</given-names></string-name>, <string-name name-style="western"><surname>Barbato</surname>  <given-names>E</given-names></string-name>, <string-name name-style="western"><surname>Berry</surname>  <given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Chieffo</surname>  <given-names>A</given-names></string-name>, <etal>et al</etal></person-group>  <article-title>2023 ESC guidelines for the management of acute coronary syndromes</article-title>. <source>Eur Heart J</source>  <year>2023</year>;<volume>44</volume>:<fpage>3720</fpage>–<lpage>3826</lpage>.<pub-id pub-id-type="pmid">37622654</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.1093/eurheartj/ehad191</pub-id></mixed-citation></ref><ref id="ytag081-B11"><label>11</label><mixed-citation publication-type="journal">
<person-group person-group-type="author">
<string-name name-style="western">
<surname>Danan</surname>  <given-names>G</given-names></string-name>, <string-name name-style="western"><surname>Benichou</surname>  <given-names>C</given-names></string-name></person-group>. <article-title>Causality assessment of adverse reactions to drugs–I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries</article-title>. <source>J Clin Epidemiol</source>  <year>1993</year>;<volume>46</volume>:<fpage>1323</fpage>–<lpage>1330</lpage>.<pub-id pub-id-type="pmid">8229110</pub-id>
<pub-id assigning-authority="pmc" pub-id-type="doi">10.1016/0895-4356(93)90101-6</pub-id></mixed-citation></ref><ref id="ytag081-B12"><label>12</label><mixed-citation publication-type="other">Lexi-Drug Interactions. UpToDate Lexidrug [Internet]. UpToDate Inc. <ext-link ext-link-type="uri" xlink:href="https://online.lexi.com/lco/action/interact" xmlns:xlink="http://www.w3.org/1999/xlink">https://online.lexi.com/lco/action/interact</ext-link>. Accessed July 20, 2025.</mixed-citation></ref></ref-list></back></article>